These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12681201)

  • 21. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
    Pechère-Bertschi A; Nussberger J; Decosterd L; Armagnac C; Sissmann J; Bouroudian M; Brunner HR; Burnier M
    J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
    Chrysant SG; Neutel JM; Ferdinand KC;
    J Natl Med Assoc; 2009 Apr; 101(4):300-7. PubMed ID: 19397219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus.
    Mugellini A; Preti P; Zoppi A; Corradi L; Fogari E; Derosa G; Fogari R
    J Hum Hypertens; 2004 Oct; 18(10):687-91. PubMed ID: 15071488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
    Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study).
    Leidig M; Bambauer R; Kirchertz EJ; Szabã T; Handrock R; Leinung D; Baier M; Schmieder RE
    Clin Nephrol; 2008 Jun; 69(6):425-32. PubMed ID: 18538118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
    Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
    Man in't Veld AJ
    J Hypertens Suppl; 1997 Dec; 15(7):S27-33. PubMed ID: 9532518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.
    Larochelle P; Flack JM; Marbury TC; Sareli P; Krieger EM; Reeves RA
    Am J Cardiol; 1997 Dec; 80(12):1613-5. PubMed ID: 9416950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk.
    Weir MR; Neutel JM; Bhaumik A; De Obaldia ME; Lapuerta P
    J Clin Hypertens (Greenwich); 2007 Dec; 9(12 Suppl 5):23-30. PubMed ID: 18046109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.
    Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman KP; Nyström F; Hägg A; Lind L;
    J Hypertens; 2001 Oct; 19(10):1783-7. PubMed ID: 11593098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
    Goldberg AI; Dunlay MC; Sweet CS
    Am J Cardiol; 1995 Apr; 75(12):793-5. PubMed ID: 7717281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
    Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.
    Neutel JM; Franklin SS; Lapuerta P; Bhaumik A; Ptaszynska A
    J Hum Hypertens; 2008 Apr; 22(4):266-74. PubMed ID: 17928878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
    Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension.
    Neutel JM; Smith D
    J Int Med Res; 2005; 33(6):620-31. PubMed ID: 16372579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome.
    Baumhäkel M; Schlimmer N; Böhm M;
    Int J Impot Res; 2008; 20(5):493-500. PubMed ID: 18596705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartan.
    de Alvaro F; Velasco O; Honorato J; Calvo C; Parrondo I;
    Kidney Int Suppl; 2005 Jan; (93):S29-34. PubMed ID: 15613064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The KARTAN study: a postmarketing assessment of Irbesartan in patients with hypertension.
    Morales-Olivas FJ; Arístegui I; Estañ L; Rodicio JL; Moreno A; Gil V; Ferrón G; Velasco O;
    Clin Ther; 2004 Feb; 26(2):232-44. PubMed ID: 15038946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
    Neutel JM; Germino FW; Smith D
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study.
    Parhofer KG; Münzel F; Krekler M
    Cardiovasc Diabetol; 2007 Nov; 6():36. PubMed ID: 18042288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.